Sun Pharma gets FDA approval for diabetes generic drug

Fri Jul 12, 2013 8:40am IST

Related Topics

Stocks

   

REUTERS - Sun Pharmaceutical Industries(SUN.NS) said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's (NOVOb.CO) Prandin diabetes drug.

Prandin, known chemically as repaglinide, and its combination with the commonly prescribed type 2 diabetes drug metformin, sold as PrandiMet, had sales of about $200 million in 2012 for Novo.

Sun Pharma said it would be eligible for a 180-day marketing exclusivity in the United States for the drug.

A U.S. appeals court last month found the patent on Novo's Prandin diabetes drug in combination with metformin to be invalid, paving the way for the introduction of a generic version of the drug.

(Reporting by Sumeet Chatterjee in MUMBAI; Editing by Supriya Kurane)

FILED UNDER:

Reuters Showcase

Uber's Woes

Uber's Woes

Uber, other taxi-hailing apps hit new roadblock in Delhi.  Full Article 

Transfer Pricing

Transfer Pricing

India's Vodafone decision eases tax worries for Shell, others.  Full Article 

Facebook Earnings

Facebook Earnings

Facebook tops Wall Street revenue target in 4th quarter.  Full Article 

Governance Reforms

Governance Reforms

IMF sets June deadline for progress on governance reforms.  Full Article 

Fed's Stance

Fed's Stance

Fed upbeat on U.S. economy, cites strong job gains.  Full Article 

Tumultuous Run

Tumultuous Run

McDonald's CEO Don Thompson leaving.  Full Article 

Samsung Results

Samsung Results

Samsung Elec's smartphone primacy under threat from Apple after weak Q4.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage